JP2011136997A5 - - Google Patents

Download PDF

Info

Publication number
JP2011136997A5
JP2011136997A5 JP2011000275A JP2011000275A JP2011136997A5 JP 2011136997 A5 JP2011136997 A5 JP 2011136997A5 JP 2011000275 A JP2011000275 A JP 2011000275A JP 2011000275 A JP2011000275 A JP 2011000275A JP 2011136997 A5 JP2011136997 A5 JP 2011136997A5
Authority
JP
Japan
Prior art keywords
nucleic acid
protein
nucleotide sequence
mammal
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011000275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011136997A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011136997A publication Critical patent/JP2011136997A/ja
Publication of JP2011136997A5 publication Critical patent/JP2011136997A5/ja
Withdrawn legal-status Critical Current

Links

JP2011000275A 2003-09-17 2011-01-04 コンセンサス／先祖免疫原 Withdrawn JP2011136997A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50346003P 2003-09-17 2003-09-17
US60/503,460 2003-09-17
US60472204P 2004-08-27 2004-08-27
US60/604,722 2004-08-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006527030A Division JP4773352B2 (ja) 2003-09-17 2004-09-17 コンセンサス／先祖免疫原

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013253689A Division JP6165612B2 (ja) 2003-09-17 2013-12-06 コンセンサス／先祖免疫原

Publications (2)

Publication Number Publication Date
JP2011136997A JP2011136997A (ja) 2011-07-14
JP2011136997A5 true JP2011136997A5 (enExample) 2011-08-25

Family

ID=34381074

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006527030A Expired - Fee Related JP4773352B2 (ja) 2003-09-17 2004-09-17 コンセンサス／先祖免疫原
JP2011000275A Withdrawn JP2011136997A (ja) 2003-09-17 2011-01-04 コンセンサス／先祖免疫原
JP2013253689A Expired - Fee Related JP6165612B2 (ja) 2003-09-17 2013-12-06 コンセンサス／先祖免疫原

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006527030A Expired - Fee Related JP4773352B2 (ja) 2003-09-17 2004-09-17 コンセンサス／先祖免疫原

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013253689A Expired - Fee Related JP6165612B2 (ja) 2003-09-17 2013-12-06 コンセンサス／先祖免疫原

Country Status (10)

Country Link
US (3) US8071107B2 (enExample)
EP (2) EP2371387A3 (enExample)
JP (3) JP4773352B2 (enExample)
KR (2) KR20070028291A (enExample)
CN (2) CN1852734B (enExample)
AU (1) AU2004274937B9 (enExample)
BR (1) BRPI0414443A (enExample)
CA (2) CA2918585C (enExample)
IL (3) IL174380A0 (enExample)
WO (1) WO2005028625A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02007478A (es) 2000-02-04 2004-08-23 Univ Duke Vacuna contra el virus de inmunodeficiencia humana.
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
AU9466701A (en) 2000-09-22 2002-04-02 Univ Duke Immunogen
CN1852734B (zh) 2003-09-17 2010-12-01 杜克大学 共有/祖先免疫原
US8048431B2 (en) * 2003-09-17 2011-11-01 Duke University Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
EP1800126B1 (en) 2004-09-08 2014-12-17 The United States of America as represented by the Secretary of Health and Human Services, NIH Compositions and methods for the detection of hiv-1/hiv-2 infection
CA2620874A1 (en) 2005-08-23 2007-03-01 The Regents Of The University Of California Polyvalent vaccine
US7951377B2 (en) * 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
KR20080106467A (ko) * 2006-03-10 2008-12-05 펩트셀 리미티드 Ｈｉｖ 조절 또는 보조 단백질의 펩타이드, 그 조성물 및 이용 방법
WO2007126959A2 (en) * 2006-03-29 2007-11-08 Dana-Farber Cancer Institute Methods and compositions for inducing an immune response to hiv and models for testing
AU2007256717B2 (en) * 2006-06-02 2013-06-20 International Aids Vaccine Initiative HIV-1 Clade A consensus sequences, antigens, and transgenes
AU2015234338C1 (en) * 2006-07-28 2017-07-20 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
CN105063064B (zh) * 2006-07-28 2024-09-24 宾夕法尼亚大学托管会 改进的疫苗及其使用方法
CA2682206A1 (en) * 2007-03-27 2008-10-02 The Regents Of The University Of California Acute transmitted hiv envelope signatures
HRP20181776T1 (hr) 2008-11-18 2019-02-08 Beth Israel Deaconess Medical Center, Inc. Antivirusna cjepiva sa poboljšanom staničnom imunogenosti
JP2013520498A (ja) * 2010-02-25 2013-06-06 デューク ユニバーシティー 防御的抗ｈｉｖ−１抗体の産生を誘導する方法
WO2011109104A2 (en) * 2010-03-03 2011-09-09 The Uab Research Foundation Molecular clone of hiv-1
WO2012047267A2 (en) * 2010-09-28 2012-04-12 Duke University Polyvalent immunogen
EP2492279A1 (en) * 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
US10040826B2 (en) 2011-07-05 2018-08-07 Duke University Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens
CA2850745C (en) * 2011-10-03 2022-12-13 Duke University Vaccine
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
ES2718899T3 (es) 2012-03-02 2019-07-05 Us Gov Health & Human Services Método para modificar la jerarquía de inmunodominio de gag del VIH mediante una vacuna de ADN que expresa regiones conservadas
SG11201500439RA (en) * 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
KR101826536B1 (ko) 2012-08-07 2018-02-07 현대자동차 주식회사 차량의 아이들 스톱 제어 방법 및 장치
US9675687B2 (en) * 2013-03-15 2017-06-13 University Of Massachusetts Compositions and methods to treat AIDS
EP3058065B1 (en) * 2013-10-16 2018-05-02 New England Biolabs, Inc. Reverse transcriptase with enhanced properties
MA40783A (fr) * 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
WO2017007646A1 (en) * 2015-07-07 2017-01-12 International Aids Vaccine Initiative Hiv-1 clade c envelope glycoproteins
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
EP3423091A4 (en) 2016-03-03 2019-10-30 Duke University COMPOSITIONS AND METHODS OF INDUCING HIV-1 ANTIBODIES
PT3512543T (pt) * 2016-09-15 2020-10-13 Janssen Vaccines & Prevention Bv Trímero que estabiliza mutações das proteínas do envelope do hiv
US10828363B1 (en) 2016-09-16 2020-11-10 The Trustees Of The University Of Pennsylvania Extreme polyvalency induces potent cross-clade cellular and humoral responses in rabbits and non-human primates
EP3519428A4 (en) 2016-10-03 2020-07-08 Duke University METHODS OF IDENTIFYING IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS
EP3526236B1 (en) 2016-10-17 2025-12-10 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
WO2020072169A1 (en) 2018-10-01 2020-04-09 Duke University Hiv-1 envelope stabilizing mutations
GB201816873D0 (en) * 2018-10-17 2018-11-28 Imperial Innovations Ltd Fusion protein
CA3145791A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
KR20230131481A (ko) 2021-01-14 2023-09-13 길리애드 사이언시즈, 인코포레이티드 Hiv 백신 및 이의 사용 방법
US20250213675A1 (en) * 2022-03-31 2025-07-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Immunogens and vaccine compositions against hiv
WO2025072797A2 (en) * 2023-09-27 2025-04-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Immunogens and vaccine compositions against hiv

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US20030096778A1 (en) * 2002-06-13 2003-05-22 Shiver John W Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
US7655774B2 (en) 2000-02-18 2010-02-02 University Of Washington Ancestral and COT viral sequences, proteins and immunogenic compositions
JP2003523188A (ja) * 2000-02-18 2003-08-05 ユニバーシティ・オブ・ワシントン Ａｉｄｓ先祖ウイルスおよびワクチン
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
AU9466701A (en) 2000-09-22 2002-04-02 Univ Duke Immunogen
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
CN1852734B (zh) 2003-09-17 2010-12-01 杜克大学 共有/祖先免疫原
US8048431B2 (en) 2003-09-17 2011-11-01 Duke University Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
HRP20040589B1 (en) 2004-06-28 2011-07-31 Biljan Marijan The stand for garment hangers with a built-in counter

Similar Documents

Publication Publication Date Title
JP2011136997A5 (enExample)
JP2011530309A5 (enExample)
JP2012126742A5 (enExample)
JP2013172734A5 (enExample)
ES2662801T3 (es) Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas
JP2011155981A5 (enExample)
EP4303232A3 (en) Chimeric antigen receptor and methods of use thereof
HUE055505T2 (hu) Anti-CGRP készítmények és alkalmazásuk
HUE053720T2 (hu) ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
CO7151522A2 (es) Proteínas de fusión de interleuquina-10 y usos de las mismas
CL2013002361A1 (es) Metodo para medir actividad de células natural killer (nk); kit para medir dicha actividad; proteína de fusión; composicion para activar células nk; polipéptido, oligonucleótido, vector y célula hospedera que comprenden la proteína;
TN2014000438A1 (en) Anti-fcrn antibodies
MX346475B (es) Peptidos inmunogenicos monomericos y multimericos.
EA201391183A1 (ru) Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин
EP2897640A4 (en) HEPATITIS B VIRUS CORE PROTEIN AND SURFACE ANTIBODY PROTEIN AND VACCINE THEREWITH
CL2012002016A1 (es) Vector para vacunas que comprende un polipeptido antigénico y un polipéptido hmgb1 o un fragmento funcional; composición que comprende el vector; método para potenciar respuesta inmune en un sujeto.
PL2776460T3 (pl) Białko fuzyjne zawierające interleukinę 4 i interleukinę 10
IN2012DN03209A (enExample)
HUE050438T2 (hu) Rekombináns fehérjék és terápiás alkalmazásuk
WO2011094357A8 (en) Respiratory virus epitopes templated into double stranded coiled -coils and use thereof in immunization
EP2528939A4 (en) RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH
JP2013100370A5 (enExample)
WO2014060851A3 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
MX358507B (es) Antigenos vacunales quimericos contra el virus de la hepatitis c.
JP2016506945A5 (enExample)